A MERS vaccine, which uses RNA-based adjuvants, has demonstrated efficacy in non-human primates and is now being developed as a prophylactic for COVID-19.

A Korean research team has developed a new vaccine platform using RNA-based adjuvants for the Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV), which showed promise in non-human primates. The scientists say the vaccine will soon be applicable to the development of a SARS-CoV-2 vaccine, another coronavirus causing the COVID-19 pandemic. 

The Korea Institute of Science and Technology (KIST) team and collaborators used RNA as an immunostimulatory agent and consists of compounds that maintain the stability of the RNA, along with the coronavirus Spike (S) protein that the virus uses to invade the host cell.